DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
Enterome
Fusion Pharmaceuticals Inc.
Debiopharm International SA
Day One Biopharmaceuticals, Inc.
Hutchmed
Orano Med LLC
Hutchmed
Ascentage Pharma Group Inc.
Sichuan Huiyang Life Science and Technology Corporation
Aminex Therapeutics, Inc.
Radionetics Oncology
Rain Oncology Inc
Ipsen
Hoffmann-La Roche
Ipsen
Ipsen
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Fore Biotherapeutics
Novartis
Daiichi Sankyo
Novartis
Ipsen
Eisai Inc.
AstraZeneca
Eli Lilly and Company
Jiangsu HengRui Medicine Co., Ltd.
Ipsen
AbbVie
Novartis
Novartis
Novartis
INSYS Therapeutics Inc
Corcept Therapeutics
Mateon Therapeutics
Molecular Insight Pharmaceuticals, Inc.
Precision Therapeutics